-
Fulzerasib Tablets Approved with Conditions for Marketing by China NMPA
2025-02-19
Recently, the Category 1 innovative drug Fulzerasib Tablets (trade name:达伯特) of Innovent Biologics, Inc. is approved with condition for marketing through the priority review and approval procedure by China NMPA.
-
Tendvia™ Pulmonary Artery Thrombectomy System Approved for Marketing
2025-02-19
Recently, the innovative product Tendvia™ Pulmonary Artery Thrombectomy System of Shanghai Tendfo Medical Device Co., Ltd. is approved by China NMPA.
-
Transjugular Intrahepatic Puncture Device Approved for Marketing
2025-02-19
Recently, the innovative product "transjugular intrahepatic puncture device" of Beijing Ailin Medical Technology Co., Ltd. is approved for marketing by China NMPA.
-
Disposable Radiofrequency Atrial Septal Puncture Needle Approved for Marketing
2025-02-19
Recently, the innovative product Disposable Radiofrequency Atrial Septal Puncture Needle of Hangzhou Nuosheng Medical Technology Co., Ltd. is approved for marketing by China NMPA.
-
Auxiliary Diagnosis Software for Fundus Images of Fundus Lesions Approved for Marketing
2025-02-19
Recently, the Auxiliary Diagnosis Software for Fundus Images of Fundus Lesions of Visionary Intelligence Ltd. is approved for marketing by China NMPA.
-
Cryoablation Apparatus Approved for Marketing
2025-02-19
Recently, the innovative product Cryoablation Apparatus of Shanghai Antaike Medical Technology Co., Ltd. is approved for marketing by China NMPA.
